Advertise with us
[October 20, 2004]
Biophan Technologies to Present at WallSt.net Small Cap Conference
ROCHESTER, N.Y. --(Business Wire)-- Oct. 20, 2004 -- Biophan Technologies, Inc. (OTC BB: BIPH), a developer of next-generation biomedical technology, has announced it will present an overview of the Company to investment professionals attending the WallSt.net Small Cap Conference in Beverly Hills, CA, on Friday, Oct. 22. Biophan's CEO, Michael Weiner, will be making the presentation.
WallSt.net's Small Cap Conference, to be held at the Four Seasons Hotel in Beverly Hills, CA, will be attended by a variety of small cap brokers, fund managers, and investment bankers.
Mr. Weiner will discuss Biophan's leading role in the development of technologies to make implantable biomedical devices and surgical tools safe and compatible with the Magnetic Resonance Imaging (MRI) environment, as well as several new technology initiatives.
"I look forward to meeting with the investment professionals in the Los Angeles area who will be attending this event," said Mr. Weiner. "Biophan has recently announced several important new initiatives in the biomedical device arena, including NanoView MRI contrast agents, implantable power systems powered by body heat, and drug delivery technologies. These are in addition to our technologies for making devices both safe and imageable under MRI. We have recently provided demonstrations of our effectiveness, including our "anti-antenna" technology. Four of our six technologies utilize advances in nanotechnology, and we have now reached 92 patents, pending and issued. We will also review our joint development agreements with both NASA and Boston Scientific (NYSE: BSX).
WallSt.net, owned by Digital Wall Street, is an online open network financial community that provides a number of services and tools to investors, including financial and market news, reports, and conferences. It can be found at www.WallSt.net.
About Biophan Technologies
Biophan develops and markets cutting-edge technologies designed to make biomedical devices safe and compatible with the magnetic resonance imaging (MRI) environment. The Company develops enabling technologies for implanted medical systems such as pacemakers, and interventional surgical devices such as catheters and guidewires, as well as stents and other implants that can be safely and effectively imaged under MRI. The technology is also being used to create MRI contrast agents, and has expanded to include other applications, such as drug delivery and power systems derived from body heat. Four Biophan product lines include advances in nanotechnology and thin film coatings. Committed to growth through innovation and developmental leadership, Biophan and its licensors have 21 issued U.S. patents and 71 patents pending, in areas including nanotechnology (nanomagnetic particle coatings), radio frequency filters, polymer composites, thermoelectric materials for batteries generating power from body heat, and photonics. Biophan has joint development arrangements with Boston Scientific (NYSE:BSX - News) and NASA's Ames Center for Nanotechnology. Biophan's goal is to make all biomedical devices capable of safely and successfully working with MRI, and delivering other technologies which will improve quality of life. For more information, please visit www.biophan.com.
Cautionary Statement Regarding Forward-Looking Statements
Certain statements included in this press release may constitute forward-looking statements. Actual results could differ materially from such statements expressed or implied herein as a result of a variety of factors including, but not limited to: the development of Biophan's MRI technologies; the approval of Biophan's patent applications; the successful implementation of Biophan's research and development programs; the acceptance by the market of Biophan's products; competition and the timing of projects and trends in future operating performance, as well as other factors expressed from time to time in Biophan's periodic filings with the Securities and Exchange Commission (the "SEC"). As a result, this press release should be read in conjunction with Biophan's periodic filings with the SEC. The forward-looking statements contained herein are made only as of the date of this press release, and Biophan undertakes no obligation to publicly update such forward-looking statements to reflect subsequent events or circumstances.
Back To NFVZone's Homepage